Search research articles
Contact Us
Filters
Showing results (101-110 of 135) with videos related to
Page
of 14
Sort By:
Journal of Virology
|
July 3, 2023
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
Jaime L Jensen, Rajeshwer S Sankhala, Vincent Dussupt, et al.
Iscience
|
October 1, 2024
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity
Elizabeth J Martinez, William C Chang, Wei-Hung Chen, et al.
Annals of the New York Academy of Sciences
|
January 14, 2022
Innovative vaccine approaches-a Keystone Symposia report
Jennifer Cable, Rino Rappuoli, Elizabeth J Klemm, et al.
Cell Reports. Medicine
|
April 6, 2023
Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques
Jingyou Yu, Paul V Thomas, Michaela Sciacca, et al.
NPJ Vaccines
|
August 20, 2022
Author Correction: Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets
In-Jeong Kim, Paula A Lanthier, Madeline J Clark, et al.
Vaccines
|
October 28, 2025
Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient Transfection
Agnes Hajduczki, William C Chang, Rafael De La Barrera, et al.
Emerging Microbes & Infections
|
December 13, 2023
Lassa virus in novel hosts: insights into the epidemiology of lassa virus infections in southern Nigeria
Anise Nkenjop Happi, Olusola Akinola Ogunsanya, Akeemat Opeyemi Ayinla, et al.
Virus Evolution
|
June 24, 2026
Genomic epidemiology and evolutionary analysis of Lassa virus from small mammals suggest bidirectional viral movement across humans and animals
Anise N Happi, Olusola A Ogunsanya, Ayotunde E Sijuwola, et al.
Lancet (London, England)
|
December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials
Kayvon Modjarrad, Leyi Lin, Sarah L George, et al.
NPJ Vaccines
|
November 20, 2024
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Kayvon Modjarrad, Ye Che, Wei Chen, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 135) with videos related to
Sort By:
Page
of 14
Journal of Virology
|
July 3, 2023
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
Jaime L Jensen, Rajeshwer S Sankhala, Vincent Dussupt, et al.
Iscience
|
October 1, 2024
SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity
Elizabeth J Martinez, William C Chang, Wei-Hung Chen, et al.
Annals of the New York Academy of Sciences
|
January 14, 2022
Innovative vaccine approaches-a Keystone Symposia report
Jennifer Cable, Rino Rappuoli, Elizabeth J Klemm, et al.
Cell Reports. Medicine
|
April 6, 2023
Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques
Jingyou Yu, Paul V Thomas, Michaela Sciacca, et al.
NPJ Vaccines
|
August 20, 2022
Author Correction: Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets
In-Jeong Kim, Paula A Lanthier, Madeline J Clark, et al.
Vaccines
|
October 28, 2025
Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient Transfection
Agnes Hajduczki, William C Chang, Rafael De La Barrera, et al.
Emerging Microbes & Infections
|
December 13, 2023
Lassa virus in novel hosts: insights into the epidemiology of lassa virus infections in southern Nigeria
Anise Nkenjop Happi, Olusola Akinola Ogunsanya, Akeemat Opeyemi Ayinla, et al.
Virus Evolution
|
June 24, 2026
Genomic epidemiology and evolutionary analysis of Lassa virus from small mammals suggest bidirectional viral movement across humans and animals
Anise N Happi, Olusola A Ogunsanya, Ayotunde E Sijuwola, et al.
Lancet (London, England)
|
December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials
Kayvon Modjarrad, Leyi Lin, Sarah L George, et al.
NPJ Vaccines
|
November 20, 2024
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Kayvon Modjarrad, Ye Che, Wei Chen, et al.
Page
of 14